LivaNova PLC
$ 76.22
0.58%
07 Aug - close price
- Market Cap 4,187,034,000 USD
- Current Price $ 76.22
- High / Low $ 76.34 / 74.67
- Stock P/E 22.35
- Book Value 22.06
- EPS 3.41
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.15 %
- 52 Week High 85.76
- 52 Week Low 48.78
About
LivaNova PLC, a medical device company, designs, develops, manufactures and sells therapeutic solutions globally. The company is headquartered in London, the United Kingdom.
Analyst Target Price
$89.40
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-05 | 2026-05-06 | 2026-02-25 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-25 | 2024-10-30 | 2024-07-31 | 2024-05-01 | 2024-02-21 | 2023-11-01 |
| Reported EPS | 1.02 | 0.98 | 0.86 | 0.97 | 1.05 | 0.88 | 0.81 | 0.9 | 0.93 | 0.73 | 0.87 | 0.73 |
| Estimated EPS | 0.96 | 0.9 | 0.8104 | 0.78 | 0.87 | 0.76 | 0.8006 | 0.72 | 0.78 | 0.49 | 0.77 | 0.64 |
| Surprise | 0.06 | 0.08 | 0.0496 | 0.19 | 0.18 | 0.12 | 0.0094 | 0.18 | 0.15 | 0.24 | 0.1 | 0.09 |
| Surprise Percentage | 6.25% | 8.8889% | 6.1204% | 24.359% | 20.6897% | 15.7895% | 1.1741% | 25% | 19.2308% | 48.9796% | 12.987% | 14.0625% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LIVN
2026-08-06 18:09:50
LivaNova PLC (LIVN) reported record revenue of $391 million and adjusted EPS of $1.26 for Q2 2026, driven by strong growth in both Cardiopulmonary and Epilepsy segments. The company raised its full-year 2026 revenue guidance to 8%-9% growth and adjusted EPS guidance to $4.30-$4.40, reflecting robust operational performance. Despite these positive results, the company lowered its free cash flow guidance due to increased capital spending and an OSA program timeline delay.
2026-08-06 17:10:22
FMR LLC has filed a Schedule 13G, disclosing a beneficial ownership of 5.8% in LivaNova PLC (LIVN) common stock, amounting to 3,210,395.27 shares as of June 30, 2026. Both FMR LLC and Abigail P. Johnson reported this stake, with FMR LLC holding sole voting power over most shares and both entities having sole dispositive power. This filing indicates a passive investment, not intended to influence company control.
2026-08-06 17:10:22
LivaNova PLC (LIVN) has seen its average 12-month price target increased from $86.78 to $88.78 by 9 analysts, with individual forecasts ranging from $75 to $95. This new target suggests a potential upside of approximately 4% from its closing price on August 4. The consensus rating from 11 analysts remains a "Buy," with 8 Buy recommendations, 2 Holds, and 1 Sell.
2026-08-05 13:43:20
LivaNova (LIVN) reported strong Q2 2026 earnings, with revenue of $390.6 million and EPS of $1.26, surpassing Wall Street expectations. The company exceeded consensus estimates for net sales in Neuromodulation, Cardiopulmonary, and Other segments. Despite the positive results, LivaNova's stock performance over the past month lagged the S&P 500, though it currently holds a Zacks Rank #2 (Buy).
2026-08-05 10:43:20
LivaNova plc (LIVN) exceeded analyst expectations for its Q2 earnings, reporting an EPS of $1.26 against an estimated $1.09, and revenue of $390.6 million compared to the $380.57 million consensus. The company also provided optimistic guidance for FY2026 EPS, projecting $4.30-$4.40, which is above the analyst consensus of $4.25. The stock price showed a significant decrease of 10.82% on the day.
2026-08-05 10:43:20
LivaNova PLC (LIVN) announced Q2 revenue of $390.6 million, surpassing the FactSet estimate of $380.5 million. The company also reported Q2 adjusted EPS of $1.26 per share, exceeding the FactSet estimate of $1.09, and raised its fiscal 2026 adjusted EPS outlook to a range of $4.30 to $4.40, against an earlier FactSet estimate of $4.25.
